Tandem Diabetes Care Inc. (TNDM)
Does TNDM Stock Still Deserve a Place in Your Portfolio?
Tandem Diabetes Care, Inc. TNDM is well-poised to grow in the coming quarters as the rising prevalence of diabetes and increasing adoption of connected care continue to support demand for automated insulin delivery. The company's pay-as-you-go reimbursement model could lower upfront barriers for pump starts and support higher supply revenue per customer over time.
Tandem Diabetes Care, Inc. (TNDM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Tandem Diabetes Care, Inc. (TNDM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Wall Street Analysts See a 56.2% Upside in Tandem Diabetes Care (TNDM): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 56.2% in Tandem Diabetes Care (TNDM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Reasons to Add Tandem Diabetes Stock to Your Portfolio Right Now
TNDM's pay-as-you-go shift, international expansion and strong liquidity support growth, while macro and reimbursement risks remain.
Tandem Diabetes Valuation: Is 1.1x Sales a Buy?
TNDM trades near 1.1x forward sales as it shifts to pharmacy pay-as-you-go and expands Europe, with a $21 target tied to 1.3x sales.
TNDM Stock: What to Know About Tandem's 2026 Reset
Tandem Diabetes' Q1 beat, fatter margins and positive cash flow fuel its 2026 reset as it shifts more U.S. pump starts to pay-as-you-go pharmacy.
TNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin Up
Tandem Diabetes beats Q1 revenue and earnings estimates as gross margin expands, but shares decline 23.6% after the results announcement.
Tandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tandem Diabetes Care (TNDM) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Tandem Diabetes Care (TNDM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Tandem Diabetes Care, Inc. (TNDM) Q1 2026 Earnings Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q1 2026 Earnings Call Transcript
Tandem Diabetes Care Q1 Earnings Call Highlights
Tandem Diabetes Care NASDAQ: TNDM reported record first-quarter pump shipments and sales for 2026, while reaffirming its full-year outlook as the diabetes technology company advances a shift toward pharmacy-channel reimbursement, expands direct international operations and prepares several product launches.
Compared to Estimates, Tandem Diabetes Care (TNDM) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
